Hernández‐Novoa, B
16  Ergebnisse:
Personensuche X
?
2

Effect of 24 weeks of intensification with a CCR5‐antagonis..:

Díaz, L ; Gutiérrez, C ; Page, C...
Journal of the International AIDS Society.  13 (2010)  S3 - p. , 2010
 
?
5

Virological response to short-course maraviroc monotherapy ..:

Hernandez-Novoa, B. ; Madrid-Elena, N. ; Dronda, F....
Journal of Antimicrobial Chemotherapy.  69 (2014)  7 - p. 1916-1919 , 2014
 
?
7

Raltegravir pharmacokinetics in HIV/HCV-coinfected patients..:

Hernandez-Novoa, B. ; Moreno, A. ; Perez-Elias, M. J....
Journal of Antimicrobial Chemotherapy.  69 (2013)  2 - p. 471-475 , 2013
 
?
8

What Drives the Number of High-Risk Human Papillomavirus Ty..:

Del Amo, J. ; Gonzalez, C. ; Geskus, R. B....
Journal of Infectious Diseases.  207 (2013)  8 - p. 1235-1241 , 2013
 
?
10

30LB Maraviroc administration is associated to reversion of..:

N. Madrid-Elena ; L. García-Bermejo ; Adíaz-De Santiago...
http://www.sciencedirect.com/science/article/pii/S2055664020309754.  , 2016
 
?
11

LEDGF/p75 TATA-less promoter is driven by the transcription..:

Desfarges, S ; Abderrahmani, A ; Hernàndez-Novoa, B..
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jmb.2011.10.010.  , 2011
 
?
 
?
13

What Drives the Number of High-Risk Human Papillomavirus Ty..:

Del Amo, Julia ; González, Cristina ; Geskus, Ronald B....
The Journal of Infectious Diseases.  207 (2013)  8 - p. 1235-1241 , 2013
 
?
14

What Drives the Number of High-Risk Human Papillomavirus Ty..:

Del Amo, Julia ; González, Cristina ; Geskus, Ronald B....
The Journal of Infectious Diseases.  207 (2013)  8 - p. 1235-1241 , 2013
 
1-15